Abstract: The present disclosure provides technologies for performing in vitro transcription that can generate product RNA preparations with reduced levels of certain contaminants (e.g., aberrant products), and particularly of double-stranded RNA (dsRNA).

Abstract: The disclosure generally relates to compositions and methods for the production of nucleic acid molecules. In some aspects, the invention allows for the microscale generation of nucleic acid molecules, optionally followed by assembly of these nucleic acid molecules into larger molecules. In some aspects, the invention allows for efficient production of nucleic acid molecules (e.g., large nucleic acid molecules such as genomes).

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: A compensating element having a first and a second assembly, wherein a locking mechanism is provided which can be switched over between a first and a second operating state. In the first operating state, the first assembly is connected fixedly to the second assembly and, in the second operating state, the first and second assemblies are connected to each other via a spring mechanism in such a manner that they are movable relative to each other. The locking mechanism includes an electric motor that can be used to switch over between the first and the second operating state. A locking ring is or is not braced against at least three balls depending on its rotational position with respect to a center axis. The locking ring is connected in terms of rotary drive to the electric motor via a torsion spring which is elastic with respect to the center axis.

Abstract: The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products. Various aspects of such packaging, transportation, and storage are provided herein for ultra-low temperature materials useful for the treatment and/or prevention of disease. The present disclosure also provides packaging materials, methods of transportation, and methods of storage for maintaining biological and/or pharmaceutical materials at ultra-low temperatures in order to maintain the integrity of the materials. The present disclosure further relates to the field of RNA to prevent or treat coronavirus infection.

Abstract: A process for preparing a porous carbon material. The process comprises the process steps: providing a carbon source; providing an amphiphilic species; contacting the carbon source and the amphiphilic species to obtain a precursor; and heating the precursor to obtain the porous carbon material; wherein the carbon source comprises a carbon source compound, wherein the carbon source compound comprises an aromatic ring having one or more attached OH groups and an ester link.

Abstract: A process for the preparation of a porous carbon material using an improved amphiphilic species. Also disclosed are a porous carbon material, devices comprising the porous carbon material and use of an amphiphilic compound for the preparation of a porous carbon material. The process for preparing a porous carbon material comprises the process steps: (a) providing a carbon source comprising a first carbon source compound; (b) providing an amphiphilic species comprising a first amphiphilic compound, the first amphiphilic compound comprising two or more adjacent ethylene oxide-based repeating units; (c) contacting the carbon source and the amphiphilic species to obtain a precursor; and (d) heating the precursor to obtain the porous carbon material.

Abstract: A process for the preparation of a porous carbon material using an improved amphiphilic species. Also disclosed are a porous carbon material, devices comprising the porous carbon material and use of an amphiphilic compound for the preparation of a porous carbon material. The process for preparing a porous carbon material comprises the process steps: (a) providing a carbon source comprising a first carbon source compound; (b) providing an amphiphilic species comprising a first amphiphilic compound, the first amphiphilic compound comprising two or more adjacent ethylene oxide-based repeating units; (c) contacting the carbon source and the amphiphilic species to obtain a precursor; and (d) heating the precursor to obtain the porous carbon material.

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

Abstract: The present disclosure provides technologies for in vitro transcription reactions, particularly for production of pharmaceutical grade RNA, and in some embodiments for large scale production.

Abstract: A process for preparing a porous carbon material. The process comprises the process steps: providing a carbon source; providing an amphiphilic species; contacting the carbon source and the amphiphilic species to obtain a precursor; and heating the precursor to obtain the porous carbon material; wherein the carbon source comprises a carbon source compound, wherein the carbon source compound comprises an aromatic ring having one or more attached OH groups and an ester link.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: A method is for controlling a nuclear power plant comprising pressurized water nuclear reactor (3) having a reactor core producing power, a primary circuit (5) connecting the reactor core to a steam generator (9), one or more of control rods (16), which can be moved into the reactor core for controlling the power of the reactor core, an injecting device (22, 23, 24, 26, 28, 30) for injecting boric acid and/or deionized water into the primary circuit (5) for controlling the reactivity of the reactor core.

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

Abstract: A device for identifying and monitoring the state of an arrangement to be monitored having an openable and closable wing element is provided. The device has a housing, which has a housing base securable on or connected in one piece to the arrangement and a second housing part attachable to and removable from the housing base. The device is also provided with an identification marker, the housing base has a first identification marker for the arrangement to be monitored having an openable and closable wing element, and the second housing part has at least one second identification marker identifying the second housing part.

Abstract: Disclosed herein are RNA polynucleotides comprising a 5? Cap, a 5? UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

Abstract: Disclosed herein are RNA polynucleotides comprising a 5? Cap, a 5? UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.